Merus N.V. (MRUS)

Market Cap	3.52B
Revenue (ttm)	38.34M
Net Income (ttm)	-149.65M
Shares Out	66.24M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	865,556
Open	54.50
Previous Close	54.45
Day's Range	52.82 - 55.28
52-Week Range	19.81 - 61.61
Beta	1.10
Analysts	Strong Buy
Price Target	76.00 (+43.15%)
Earnings Date	Aug 5, 2024

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 19, 2016
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: MRUS

Financial Performance

In 2023, Merus's revenue was $43.95 million, an increase of 5.68% compared to the previous year's $41.59 million. Losses were -$154.94 million, 18.1% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for MRUS stock is "Strong Buy." The 12-month stock price forecast is $76.0, which is an increase of 43.15% from the latest price.

Price Target

$76.0

(43.15% upside)

Analyst Consensus: Strong Buy